NCT06599528View on ClinicalTrials.gov

A Comparing Study Between SJ04 and Ovidrel® in Healthy Subjects

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

August 12, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Assisted Reproductive TechnologyFemale Infertility
Interventions
DRUG

T-R (Test-Reference drug)

T: SJ04 (Test drug) R: Ovidrel® (Referecne drug) 250 μg of SJ04 injection or Oviderl®, administered subcutaneously once at two week intervals.

DRUG

R-T (Reference-Test drug)

R: Ovidrel®(Referecne drug) T: SJ04 (Test drug) 250 μg of SJ04 or Oviderl®, administered subcutaneously once at two week intervals.

Trial Locations (1)

215000

RECRUITING

Suzhou Municipal Hospital, Suzhou

All Listed Sponsors
lead

Suzhou Centergene Pharmaceuticals Co.,Ltd.

INDUSTRY